American Express Co vs Davita Inc — how do they compare? American Express Co trades at $340.05 (market cap $230.15B), while Davita Inc trades at $179.02 (market cap $11.38B). The key difference: American Express Co is far larger — about 20.2× Davita Inc's market cap, and American Express Co pays a 1.11% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| AXP | DVA | |
|---|---|---|
Market Cap | $230.15B | $11.38B |
Sector | Financials | Health |
52-Week High | $384.82 | $240.96 |
52-Week Low | $292.27 | $103.87 |
Dividend Yield | 1.11% | — |
Enterprise Value | — | $24.10B |
Signals from Pluang's Aura AI — not financial advice
American Express (AXP) trades at $338.86, down 0.6% with bearish technical signals despite strong fundamentals. The company reported solid Q2 2026 earnings beat ($4.53 vs $4.41 expected) and maintains robust profitability with 15.07% net margin and 33.97% ROE. Recent news highlights Amex Ventures' AI investments and premium card member experiences, while Berkshire Hathaway's 20% ownership underscores long-term confidence in the business model.
AXP presents a mixed outlook with strong fundamental performance offset by technical weakness. The stock offers 9% upside to consensus price target of $369.42, supported by revenue growth and premium positioning, but faces headwinds from bearish technical indicators and competitive pressure in digital payments. Risk-reward appears balanced near current levels.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
American Express Company is a global payment and travel company. The Company's principal products and services are charge and credit payment card products and travel-related services offered to consumers and businesses around the world.
Read more on AXP →DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →